NAVCO PHARMACEUTICALS INC (NAV.CA) Stock Fundamental Analysis

Canada • TSX Venture Exchange • TSX-V:NAV • CA63942R1091

0.01 CAD
0 (0%)
Last: Jan 29, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to NAV. NAV was compared to 0 industry peers in the Unkown industry. NAV has a bad profitability rating. Also its financial health evaluation is rather negative. NAV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year NAV has reported negative net income.
  • In the past year NAV has reported a negative cash flow from operations.
NAV.CA Yearly Net Income VS EBIT VS OCF VS FCFNAV.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -500K -1M -1.5M -2M

1.2 Ratios

Industry RankSector Rank
ROA -13676.12%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NAV.CA Yearly ROA, ROE, ROICNAV.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NAV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NAV.CA Yearly Profit, Operating, Gross MarginsNAV.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • The number of shares outstanding for NAV has been increased compared to 1 year ago.
  • The debt/assets ratio for NAV is higher compared to a year ago.
NAV.CA Yearly Shares OutstandingNAV.CA Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
NAV.CA Yearly Total Debt VS Total AssetsNAV.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200K 400K 600K 800K

2.2 Solvency

  • NAV has an Altman-Z score of -1580.24. This is a bad value and indicates that NAV is not financially healthy and even has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1580.24
ROIC/WACCN/A
WACCN/A
NAV.CA Yearly LT Debt VS Equity VS FCFNAV.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 -500K -1M -1.5M

2.3 Liquidity

  • NAV has a Current Ratio of 0.01. This is a bad value and indicates that NAV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • A Quick Ratio of 0.01 indicates that NAV may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.01
Quick Ratio 0.01
NAV.CA Yearly Current Assets VS Current LiabilitesNAV.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200K 400K 600K 800K

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • NAV shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -419.35%.
EPS 1Y (TTM)-419.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • NAV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NAV.CA Price Earnings VS Forward Price EarningsNAV.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NAV.CA Per share dataNAV.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0 -0.01 -0.01

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NAV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NAVCO PHARMACEUTICALS INC

TSX-V:NAV (1/29/2026, 7:00:00 PM)

0.01

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners33.1%
Ins Owner ChangeN/A
Market Cap570.70K
Revenue(TTM)N/A
Net Income(TTM)-916.30K
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13676.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.01
Quick Ratio 0.01
Altman-Z -1580.24
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-419.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.75%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y50.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y85.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.74%
OCF growth 3YN/A
OCF growth 5YN/A

NAVCO PHARMACEUTICALS INC / NAV.CA FAQ

What is the ChartMill fundamental rating of NAVCO PHARMACEUTICALS INC (NAV.CA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to NAV.CA.


Can you provide the valuation status for NAVCO PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to NAVCO PHARMACEUTICALS INC (NAV.CA). This can be considered as Overvalued.


What is the profitability of NAV stock?

NAVCO PHARMACEUTICALS INC (NAV.CA) has a profitability rating of 0 / 10.